Deal Strengthens US Manufacturing Presence And Expands Complex Generics Portfolio
Aurobindo Pharma has received approval from the United States Federal Trade Commission (FTC) for its proposed acquisition of Lannett Company LLC, clearing a key regulatory hurdle for the $250 million transaction.
The Hyderabad based pharmaceutical major announced on Monday that its subsidiary, Aurobindo Pharma USA Inc., has secured FTC clearance for the acquisition, which is expected to be completed before the end of the month.
The transaction is valued at $250 million on a cash free, debt free basis and includes normalized working capital adjustments.
Strategic Expansion In The US Market
The acquisition is expected to significantly strengthen Aurobindo Pharma’s position in the US pharmaceutical market, particularly in the segment of complex generic medicines and non-opioid controlled substances.
Lannett Company, headquartered in Pennsylvania, is a well established generic pharmaceutical manufacturer with expertise in developing and commercializing a diversified portfolio of complex pharmaceutical products.
Through the acquisition, Aurobindo will gain access to Lannett’s existing product portfolio, development pipeline, and manufacturing capabilities, enabling the company to expand its footprint in higher-margin pharmaceutical segments.
According to the company, the deal will enhance its ability to serve patients and healthcare providers while strengthening its competitive position in one of the world’s largest pharmaceutical markets.
Strengthening Domestic US Manufacturing
One of the most significant aspects of the acquisition is the addition of Lannett’s manufacturing facility in Seymour, Indiana.
The facility has the capacity to produce approximately 4 billion doses annually and will substantially increase Aurobindo USA’s manufacturing capabilities within the United States.
Industry experts note that domestic manufacturing has become increasingly important for pharmaceutical companies as governments seek to strengthen supply chain resilience and reduce dependence on overseas production.
The acquisition aligns with ongoing US efforts to encourage local pharmaceutical manufacturing and improve medicine availability through diversified supply chains.
Immediate Financial Benefits Expected
Aurobindo Pharma stated that the transaction is expected to be immediately accretive to the group’s earnings per share (EPS), meaning the acquisition is likely to contribute positively to profitability soon after completion.
The company believes the deal will accelerate revenue growth while creating opportunities for operational synergies and product expansion.
Commenting on the development, Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA, described the acquisition as a compelling strategic opportunity.
“This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our US-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances,” Iyer said.
Expanding Portfolio Of Complex Generics
The acquisition also provides Aurobindo access to a differentiated pipeline of complex generic medicines and controlled substances, segments that often have higher entry barriers and lower competitive intensity compared to conventional generic drugs.
As pricing pressure continues to affect traditional generic pharmaceutical markets, companies are increasingly focusing on complex formulations, specialty products, and difficult-to-manufacture medicines to improve profitability and sustain growth.
Lannett’s expertise in these categories is expected to complement Aurobindo’s existing portfolio and support its long-term expansion strategy.
Positive Outlook For Both Companies
Lannett Company CEO Tim Crew welcomed the transaction, highlighting the benefits of combining the two organizations.
“Aurobindo’s market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere,” Crew said.
The deal marks another significant step in Aurobindo Pharma’s global growth strategy as the company continues expanding its manufacturing network, product portfolio, and presence in key international markets.
With FTC approval now secured, the acquisition is expected to close shortly, paving the way for Aurobindo to strengthen its position in the highly competitive US pharmaceutical industry.
